129 results about "Right heart ventricle" patented technology

Interatrial shunts are described herein that are designed to benefit both the left side of the heart and the right side of the heart. The interatrial shunt is anchored in the atrial septum to permit blood to flow between atrial heart chambers across the atrial septum. In accordance with some aspects, the lumen of the shunt has an effective orifice area selected to permit blood flow across the atrial septum to unload the patient's left ventricle with beneficial effects on the patient's right ventricle. The shunts are structured to be suitably anchored at the atrial septum for long-term implantation. Further, the shunts preferably have insignificant late lumen loss. The interatrial shunts are expected to treat pathologies such as heart failure and pulmonary hypertension.

The invention provides an intelligent auxiliary evaluation system for right ventricular systole and diastole functions of echocardiography, and aims to solve the problems of low accuracy and efficiency in right ventricular function evaluation in the prior art. The system comprises an image acquisition unit, an image processing unit, a feature extraction unit, an intelligent evaluation unit and a result output unit, and through an intelligent algorithm, especially a deep learning network DL and a convolutional neural network CNN, a feature extraction result is obtained. Key indexes such as a two-dimensional right ventricular area change fraction 2D-FAC, a right ventricular ejection fraction RVEF and tricuspid valve ring plane contraction period displacement TAPSE are automatically calculated. The system also realizes accurate evaluation of the right ventricular function through a specific CNN structure and loss function design. The system can provide rapid, accurate and non-invasive right ventricular function evaluation in clinical practice, and is helpful for improving the diagnosis and treatment effects of cardiovascular diseases.

Tricuspid valve repair devices and associated systems and methods are disclosed herein. A tricuspid valve repair device configured in accordance with embodiments of the present technology can include, for example, a coaptation member configured to be positioned between one or more native leaflets of the tricuspid valve to at least partially fill a space between the native leaflets. The tricuspid valve repair device can further include one or more fixation mechanisms for securing the coaptation member in position between the leaflets. The fixation mechanisms can include clip mechanisms, lock mechanisms, stabilization members, anchors, and / or other structures configured to engage cardiac anatomy local to or remote from the tricuspid valve, such as the native leaflets, the tricuspid valve annulus, the right ventricular outflow tract, the superior vena cava, the inferior vena cava, and so on.

A first ventricular surface anchor may be placed against the first right ventricular surface, where the first ventricular surface anchor is connected to a first tension member. A first tension anchor against a tension anchor surface of the heart wherein the first tension anchor is connected to a second tension member. The first tension member connected to the first ventricular surface anchor may extend toward the second tension member connected to the first tension anchor; and the first tension member and the second tension member may drag the first right ventricular surface toward the first tension anchor. The surface anchor may include a nitinol frame and an aperture forming an outer perimeter. When the temperature of the nitinol frame is a body temperature, the nitinol frame may have an austenitic state in a deployed configuration. The surface anchor may also include a grommet including a distal tubular portion connected to a proximal finger portion.

The invention discloses annexin A2 (ANXA2) and application of an inhibitor thereof in diagnosis, treatment and / or prevention of pulmonary arterial hypertension. In particular discloses application of an ANXA2 inhibitor (including siRNA for silencing an ANXA2 gene, an ANXA2 antibody and a phosphorylation inhibitor) in preparation of a product for preventing and / or treating pulmonary arterial hypertension. Experiments prove that the ANXA2 inhibitor can significantly inhibit proliferation and migration of pulmonary artery smooth muscle cells, and significantly improve pulmonary arterial hypertension, pulmonary artery vascular remodeling and right ventricular hypertrophy. The ANXA2 or the Thr208 phosphorylation site of the ANXA2 protein can be used for diagnosis or auxiliary diagnosis of pulmonary arterial hypertension, or used for screening drugs for pulmonary arterial hypertension and developing new diagnosis and treatment methods and drugs. The therapeutic target and the ANXA2 inhibitor developed by the invention have wide clinical application value in the fields of diagnosis, prevention and treatment of pulmonary arterial hypertension.

The invention relates to the field of medical image segmentation, in particular to a rapid and efficient heart magnetic resonance image automatic segmentation method. Firstly, a U-Net model is improved, four times of down-sampling and up-sampling of the U-Net are expanded to five times, and the resolution of the model and the capability of capturing finer features are improved; a traditional 3 * 3 convolutional layer in the U-Net is replaced by an MSRF module, and the model is helped to extract image features on different scales, so that the network can better capture multi-level information; an scSE module is added between up-sampling and jump connection of the U-Net, and the segmentation ability of the model at the right ventricle and myocardial edges is improved; and finally, combining the cross entropy loss and the Dice loss to train an MS-UNet network so as to improve the segmentation precision of the ventricular and myocardial regions at the same time. According to the method, the heart magnetic resonance image can be quickly and accurately segmented, and the segmentation speed and precision are improved.

The invention discloses a construction method of a sepsis cardiomyopathy diagnosis model and a diagnosis system, and relates to the technical field of biomedicine, and the method comprises the following steps: carrying out multi-mode ultrasonic data dynamic collection and clinical data collection on a sepsis patient; according to the multi-mode ultrasonic data, evaluating the overall and local diastolic and contraction functions of the left ventricle and the right ventricle of the heart of the patient with sepsis cardiomyopathy, and performing preliminary diagnosis of sepsis cardiomyopathy in combination with clinical data; the method comprises the following steps: dividing multi-modal ultrasonic data of a sepsis patient into a training set and a verification set by using an Rcaret packet, and carrying out minimum absolute contraction and LASSO regression analysis on the training set to determine a preliminary prediction factor; carrying out logistic regression analysis on the preliminary prediction factor, and determining an independent prediction factor; the independent predictive factors are translated in nomoscore through an rms packet to obtain a column diagram, the independent predictive factors are visually presented according to the weights of the independent predictive factors, and the probability of occurrence of sepsis cardiomyopathy is measured. According to the invention, comprehensive and dynamic quantitative evaluation of the cardiac function of the patient is realized based on the multi-modal ultrasonic parameters.

The invention discloses an application of a phosphodiesterase inhibitor in preparation of a medicine for preventing and / or treating pulmonary arterial hypertension, and the phosphodiesterase inhibitor is 1-(4-(2, 3-dihydro-1H-indeno [5, 6-b] furan-5 (4H)-keto) piperidine-4-yl)-4-chlorobenzoate. The phosphodiesterase inhibitor disclosed by the invention can effectively reduce pulmonary vascular remodeling caused by abnormal proliferation and migration of pulmonary artery smooth muscle cells, so that pulmonary artery pressure and right ventricular systolic pressure are remarkably reduced. The phosphodiesterase inhibitor disclosed by the invention has a prominent effect on inhibiting pulmonary vascular remodeling and right heart hypertrophy, has the effect of improving various clinical symptoms of pulmonary arterial hypertension, is superior to common pulmonary arterial hypertension treatment medicines at present, and has important significance on finding more new medicines for treating pulmonary arterial hypertension.

The invention discloses a cardiac magnetic resonance cardiac function evaluation method based on multi-task learning, and belongs to the technical field of medical image processing. The method comprises the following steps: labeling, enhancing and preprocessing cardiac magnetic resonance image data; training a multi-task learning model by using the preprocessed data, supervising a multi-task training process by introducing regional geometric consistency loss, and improving the accuracy and generalization performance of the model; inputting a to-be-evaluated heart magnetic resonance image into the trained multi-task learning model to obtain left and right ventricular intima segmentation results in a heart anatomical structure, a left ventricular myocardial segmentation result and a right ventricular insertion point and a left ventricular central point in a heart key point position; further calculating the ventricular volume to obtain left and right ventricular ejection fractions; calculating the thickness of each segment of the left ventricular myocardium; and outputting a cardiac function evaluation result. According to the method, the accuracy and generalization performance of the model are improved, and the problems that a traditional method is low in precision and long in analysis time consumption are solved.

The invention belongs to the technical field of medical image segmentation, and discloses a medical image segmentation method, system and device based on a twin network and multi-view fusion, and a medium, and the method comprises the steps: obtaining the sequence slice data of a heart magnetic resonance image; inputting the sequence slice data into a medical image segmentation model for image segmentation to obtain a segmentation result corresponding to each slice data; the segmentation result comprises segmentation masks of the left ventricle, the right ventricle and the cardiac muscle; the medical image segmentation model is constructed based on an encoder-decoder network, an encoder comprises a plurality of encoder branches with the same structure and unshared weights, and the encoder branches comprise an original slice image encoding branch, a region constraint slice encoder branch, a high-frequency information encoding branch and a low-frequency information encoding branch. The decoder comprises a plurality of decoding blocks with bottleneck structures. According to the invention, the accuracy and efficiency of segmentation are improved, and the robustness and applicability of the model are enhanced.

The invention relates to the technical field of biological medicines, in particular to a pharmaceutical composition and application thereof in preparation of a medicine for treating the heart-lung qi deficiency type pulmonary heart disease. The pharmaceutical composition consists of 21-27 parts of astragalus membranaceus, 13-17 parts of semen lepidii, 7-10 parts of cassia twig, 21-27 parts of ligusticum wallichii, 7-10 parts of rhizoma alismatis, 5-7 parts of platycodon grandiflorum and 2-4 parts of Chinese dates. Compared with the prior art, the cassia twig is adopted to replace fructus psoraleae in an original formula, and meanwhile, the medicinal material specifications of the fried semen descurainiae, the raw ligusticum wallichii and the salted rhizoma alismatis are preferably selected. The invention also provides three preparation methods of the pharmaceutical composition, namely a water extraction and alcohol precipitation method, an alcohol extraction and water extraction combined method and a crushing and mixing method. Experimental results show that the pharmaceutical composition has remarkable effects on improving heart functions, lung functions, blood-gas indexes, right ventricular hypertrophy and the like of pulmonary heart disease model animals, meanwhile, the hepatotoxicity risk of fructus psoraleae is avoided, and the pharmaceutical composition has a good clinical application prospect.

In some aspects, the disclosure relates to GDF / BMP antagonists and methods of using GDF3 / BMP antagonists to treat, prevent, or reduce the progression rate and / or severity of pulmonary hypertension (PH), particularly treating, preventing or reducing the progression rate and / or severity of one or more PH-associated complications. The disclosure also provides methods of using a GDF / BMP antagonist to treat, prevent, or reduce the progression rate and / or severity of a variety of conditions including, but not limited to, pulmonary vascular remodeling, pulmonary fibrosis, and right ventricular hypertrophy. The disclosure further provides methods of using a GDF / BMP antagonist to reduce right ventricular systolic pressure in a subject in need thereof.

An introductory lead system can include a first implantable lead having a first electrode and a second implantable lead having a second electrode guided to an implant site by the first implantable lead. The second electrode can be implanted in a patient's heart at the same implant site as the first electrode or at a second implant site. The introductory lead system can be delivered to one or more implant sites using various methods, including at the Koch triangle for ventricular free wall to atrium (VfA) therapy, at the right ventricular septal wall for dual bundle branch pacing, or in the coronary vasculature for left-sided sensing and pacing.

The invention relates to a simulator comprising a flexible simulation chamber simulating a living body chamber, the flexible simulation chamber having at least one opening; a valve comprising a valve leaflet; a papillary muscle entity model; and chordae tendineae connecting the papillary muscle entity model and the valve leaflets; at least one valve arm extends through the flexible simulation cavity, so that the far end of the valve arm is arranged in the flexible simulation cavity, the near end of the valve arm is arranged outside the flexible simulation cavity, the far end of the valve arm is fixed relative to the papillary muscle entity model, and the position of the far end of the valve arm can be controlled from the near end; and a control device for controlling the simulation process. Such a simulator allows for precise simulation of motion of a living body chamber, such as the left ventricle or the right ventricle of a human heart, in which case precise rotation and / or other motion of the chamber during a pulsation can be simulated.

The present invention provides novel 4-methylsulfone-substituted piperidine / urea compounds useful for the treatment of dilated cardiomyopathy (DCM) and conditions associated with left and / or right ventricular systolic dysfunction or systolic reserve. The synthesis and characterization of the compounds, as well as methods for the treatment of DCM and other forms of heart disease, are described.

Illustrative devices and methods may provide cardiac resynchronization therapy (CRT) that utilizes instantaneous CRT settings to mitigate right ventricular load during implementation of the CRT. The aggressiveness of the instantaneous CRT setting may be increased until the target CRT setting is reached. Further, the transient CRT setting may reduce aggressiveness in response to ventricular degradation.

This invention provides a wearable myocardial oxygenation monitoring device based on optical path arrangement, comprising a detection component and a control component integrated into a flexible layer. The detection component includes multi-wavelength light sources arranged at an angle of 5° to 20° to the sagittal plane of the human body, detection components partitioned according to coordinate systems of 180° to 240° and 315° to 45°, and diagonally arranged electrocardiogram electrodes. The light sources correspond to the anatomical structure of the anterior interventricular groove of the heart. The control component achieves synchronous signal acquisition and processing via an FPC circuit board. Through precise anatomical positioning, partitioned detection, and flexible fit design, this invention solves the problem of difficulty in distinguishing the functional differences between the left and right ventricles in existing technologies. An adaptive light intensity modulation mechanism based on BMI ensures the optimal balance between signal quality and energy efficiency for different body types. Multi-data fusion enhances the early warning sensitivity of myocardial ischemia, making it suitable for people of different body types and providing a reliable tool for early screening of coronary heart disease.

A first ventricular surface anchor can be placed against a first right ventricular surface, wherein the first ventricular surface anchor is connected to a first tension member. A first tension anchor against a tension anchor surface of a heart, wherein the first tension anchor is connected to a second tension member. The first tension member connected to the first ventricular surface anchor can extend towards the second tension member connected to the first tension anchor. The first tension member and the second tension member can draw the first right ventricular surface toward the first tension anchor. The surface anchor can include a nitinol frame forming an outer perimeter. The nitinol frame can have an austenite state in a deployed configuration when a temperature of the nitinol frame is body temperature. The surface anchor can also include a grommet comprising a distal tubular portion connected to a proximal finger portion.

The utility model discloses a percutaneous circulation auxiliary device. The percutaneous circulation auxiliary device comprises an intervention catheter and a diaphragm pump. The intervention catheter is provided with at least one blood inlet and at least one blood outlet, the blood inlet and the blood outlet are both one-way valves and are both in one-way conduction, and the diaphragm pump comprises a blood cavity separated by a flexible diaphragm and a driving liquid cavity used for charging and discharging liquid. When in use, the device is communicated with a liquid charging and discharging control device, is mainly used for assisting blood pumping of the right ventricle, can be placed into the right ventricle through femoral veins, assists the heart in doing work, and increases cardiac output; the utility model relates to a pulsating pump which can pump blood according to systole and diastole of the heart. The device is simple in structure and low in manufacturing cost, and has a good application prospect.

In some instances, a computing device can determine information corresponding to a data structure and indicating delays associated with atrial leads, left ventricular (LV) leads, and right ventricular (RV) leads, based on one or more input variables. The computing device can determine multiple personalized characteristics based on the information corresponding to the data structure. The computing device can receive multiple second sets of electrical measurements from multiple measuring electrodes, based on the multiple personalized characteristics, indicating a second electrical signal applied to the patient's heart. The computing device can use a first set of electrical measurements (e.g., raw measurements) and the multiple second sets of electrical measurements to determine a cardiac resynchronization index (CRI) value. The computing device can generate a graphical representation based on the populated data structure and display the graphical representation.

A first ventricular surface anchor can be placed against a first right ventricular surface, wherein the first ventricular surface anchor is connected to a first tension member. A first tension anchor against a tension anchor surface of a heart, wherein the first tension anchor is connected to a second tension member. The first tension member connected to the first ventricular surface anchor can extend towards the second tension member connected to the first tension anchor. The first tension member and the second tension member can draw the first right ventricular surface toward the first tension anchor. The surface anchor can include a nitinol frame forming an outer perimeter. The nitinol frame can have an austenite state in a deployed configuration when a temperature of the nitinol frame is body temperature. The surface anchor can also include a grommet comprising a distal tubular portion connected to a proximal finger portion.

The present invention relates to an apparatus and a method for dividing a membranous spacing. The method comprises the following steps: segmenting a left ventricular outflow tract LVOT of a heart in a 3D image data set; determining wall thickness information indicating spaced wall thicknesses at different locations of a portion of the segmented LVOT oriented toward the right ventricle and the right atrium; mapping the determined wall thickness information onto a surface of the portion of the segmented LVOT; and segmenting the membranous spacing in the 3D image dataset based on the mapped wall thickness information.

The disclosed subject matter provides systems and methods for calculating a right ventricular (RV) volume. An example system can include one or more processors configured to receive a testing image, tokenize a categorical input and a numerical input from the testing image, forward the categorical input and the numerical input to a cascaded transformer layer, transform the categorical input and the numerical input into an embedding, transform the embedding into a classification token, and provide a measurement of RV of the testing image based on the CLS token.

This invention relates to the field of biomedical technology, specifically to the application of PTPRM in the treatment and / or prevention of septic cardiomyopathy. This application found that the expression level of PTPRM was significantly reduced in the cardiac tissue of a CLP model, and further verified that overexpression of PTPRM significantly improved the survival rate of the CLP model. Furthermore, the reduction in PAT caused by CLP modeling, as well as the increases in RVDFW, RVSFW, LVSFW, LVDFW, IVS-s, and IVS-d, were also improved. In addition, overexpression of PTPRM can also reduce the expression level of cardiac troponin (cTNT) and right ventricular wall thickness. Therefore, PTPRM can be used as a target for the treatment of septic cardiomyopathy.

The invention discloses application of ellagic acid to prevention of heart injury caused by long-term diving. A medicine for preventing heart injury caused by long-term diving is a medicine composition taking ellagic acid as a unique active ingredient or containing ellagic acid. According to the application of ellagic acid in prevention of heart injury caused by long-term phreatic water, animal in-vivo experiment results show that the morbidity of myocardial infarction of a long-term simulated phreatic water rat model is reduced to 23.8% from 44.8% through ellagic acid administration, the infarction area is remarkably reduced to 4.6 + / -3.3% from 14.9 + / -7.7%, the right ventricular hypertrophy index is reduced to 23.3 + / -6.5% from 34.5 + / -12.2%, and the curative effect is remarkable. The ellagic acid can effectively prevent rat heart injury caused by long-term diving. Therefore, ellagic acid has a good application prospect in prevention of heart injury caused by long-term diving.

Compared with the prior art, the cardiac magnetic resonance image segmentation algorithm based on ShiftViT and deformable attention disclosed in the present invention pays more attention to the problems of the difficulty in fine segmentation of the edge of the myocardium and the difficulty in detecting the right ventricle area in cardiac segmentation. For the first time, ShiftViT and deformable attention technology are introduced into the automatic segmentation of the heart and the two are organically combined. The ShiftViT module obtains more contextual information through offset operation to depict the small areas of the heart; the deformable attention selects a reference area that can be learned to move to depict the edge areas between organs; combined with multi-scale input and deep supervision technology, the segmentation accuracy and efficiency of cardiac segmentation are effectively improved. Experiments have shown that in the ACDC data set, the prediction results of the present invention are: the overall segmentation Dice is 90.22, the right ventricle is 88.84, the myocardium is 87.12, and the left ventricle is 94.77. And the entire network has a greatly reduced number of parameters compared to other networks based on the attention mechanism, and the computational efficiency is greatly improved.

A method of pacing a heart includes implanting a subcutaneously implantable device on a xiphoid process and / or a sternum of a patient. The subcutaneously implantable device includes a housing, a prong extending away from the housing, and a first electrode at a distal end of the prong. The method further includes contacting a Manicka Zone of Pacing on an anterior surface of the heart with the first electrode on the distal end of the prong. The Manicka Zone of Pacing is defined as an area of the heart extending 3 centimeters (1.1811 inches) laterally outward from either side of a left anterior descending artery of the heart. A pacing signal is delivered to the Manicka Zone of Pacing of the heart through the first electrode. A right ventricle and a left ventricle of the heart are synchronously paced with the pacing signal received in the Manicka Zone of Pacing.

The application discloses a ventricular premature beat type determination method, device, equipment and medium, and the method comprises the following steps: performing feature wave identification on a periodic waveform in a to-be-identified waveform; if no feature wave exists in the periodic waveform, determining a positive wave peak value and a corresponding positive wave peak time point, and a negative wave peak value and a corresponding negative wave peak time point according to a voltage corresponding to each time point in the periodic waveform; for any time point, if a comparison result of the voltage corresponding to the time point and the positive wave peak value and the negative wave peak value satisfies a first preset condition, and a comparison result of the time point and the positive wave peak time point and the negative wave peak time point satisfies a second preset condition, then the waveform between the time point and the wave peak time point is determined as a target waveform; and according to a position of the target waveform in the periodic waveform, left ventricular premature beat or right ventricular premature beat is determined. The detection and judgment of the ventricular premature beat type are automatically realized, and the detection efficiency is improved.

The invention discloses application of scopalactone in treatment of pulmonary arterial hypertension, and relates to the technical field of medicinal chemistry. The scoparone is applied to preparation of the medicine for treating pulmonary arterial hypertension. The medicine comprises scopalactone, a pharmaceutically acceptable carrier, a diluent and an excipient, the medicine further comprises other medicines for treating the pulmonary arterial hypertension, and the other medicines for treating the pulmonary arterial hypertension are selected from a prostacyclin medicine, an endothelin receptor antagonist and a phosphodiesterase-5 inhibitor. The scopalactone is applied to preparation of the medicine for treating pulmonary arterial hypertension, right heart insufficiency caused by hypoxia can be remarkably reversed, and the right heart function is effectively improved by reducing the transverse diameter of the right ventricle and the transverse diameter of the right atrium and improving the indexes such as tricuspid valve ring plane contraction displacement; the average pulmonary arterial pressure and right ventricular systolic pressure can be obviously reduced, and hemodynamic parameters are improved; the area and thickness of a blood vessel wall can be remarkably reduced, the blood vessel structure is improved, and pulmonary arteriole reconstruction is relieved.